<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TAMOXIFEN CITRATE <img border="0" src="../images/pr.gif"/></span><br/>(ta-mox'i-fen)<br/><span class="topboxtradename">Nolvadex, </span><span class="topboxtradename">Nolvadex-D <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Tamofen <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">antiestrogen</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonsteroidal gonad-stimulating drug with potent antiestrogenic activity. Competes with estradiol at estrogen receptor sites
         in target tissues such as breast, uterus, vagina, anterior pituitary, tumor with high concentration of estrogen receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Tamoxifen-receptor complexes move into the cell nucleus, decreasing DNA synthesis and estrogen responses. Ovulation may be
         induced by stimulation of the release of hypothalamic gonadotropic-releasing factor.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative treatment of advanced breast cancer in postmenopausal women, adjunctively with surgery in the treatment of breast
         carcinoma with positive lymph nodes.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Investigationally to stimulate ovulation in selected anovulatory women desiring pregnancy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Anticoagulant therapy, pregnancy (category D), especially during first trimester; preexisting endometrial hyperplasia; intramuscular
         injections if platelets 3; history of thromboembolic disease; lactation; children.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Vision disturbances; cataracts, visual disturbance; leukopenia, bone marrow suppression; thrombocytopenia; hypercalcemia;
         hypercholesterolemia, lipid protein abnormalities.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Breast Carcinoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1020 mg 12 times/d (morning and evening)<br/><br/><span class="indicationtitle">Stimulation of Ovulation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 540 mg b.i.d. for 4 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>With severe adverse effects, a simple reduction in dosage gives sufficient relief without losing control of disease. Consult
            physician.
         </li>
<li>Store at 15°30° C (59°86° F); protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Increased bone pain, and transient local disease flair; loss of hair, weight gain, shortness of breath, photosensitivity,
      <span class="speceff-common">hot flashes</span>. <span class="typehead">CNS:</span> Depression, light-headedness, dizziness, headache, mental confusion, sleepiness. <span class="typehead">CV:</span> <span class="speceff-life">Thrombosis</span>, pulmonary embolism, increased risk of stroke. <span class="typehead">GI:</span> <span class="speceff-common">Nausea and vomiting (about 25% of patients),</span> distaste for food, anorexia. <span class="typehead">Hematologic:</span> Leukopenia, thrombocytopenia. <span class="typehead">Metabolic:</span> Hypercalcemia. <span class="typehead">Skin:</span> Skin rash or dryness. <span class="typehead">Special Senses:</span> Retinopathy, decreased visual acuity, blurred vision. <span class="typehead">Urogenital:</span> Changes in menstrual period, milk production and leaking from breasts, vaginal discharge and bleeding, pruritus vulvae, risk
      of uterine malignancies. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Tamoxifen may produce transient increase in <span class="alt">serum calcium.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May enhance hypoprothrombinemic effects of <b>warfarin;</b> may increase risk of thromboembolic events with <span class="classification">cytotoxic agents</span>; <b>bromocriptine</b> may elevate tamoxifen levels, <small>SSRI</small> <span class="classification">antidepressants</span> may decrease effectiveness of tamoxifen. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from GI tract. <span class="typehead">Peak:</span> 36 h. <span class="typehead">Metabolism:</span> Metabolized in liver, enterohepatically cycled. <span class="typehead">Elimination:</span> Excreted primarily in feces. <span class="typehead">Half-Life:</span> 7 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness. An objective response may require 410 wk of therapy, longer if there is bone metastasis.</li>
<li>Administer analgesics for pain relief as necessitated by bone and tumor pain or local disease flair. Reassure patient that
            this discomfort frequently signals a good tumor response.
         </li>
<li>Be aware that local swelling and marked erythema over preexisting lesions or the development of new lesions may signal soft-tissue
            disease response to tamoxifen. These symptoms rapidly subside.
         </li>
<li>Lab tests: Assess CBC, including platelet counts, periodically. Transient leukopenia and thrombocytopenia (50,000100,000/mm<sup>3</sup>) without hemorrhagic tendency have been reported. Monitor serum calcium periodically.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not change established dose schedule.</li>
<li>Report to physician occurrence of marked weakness, sleepiness, mental confusion, edema, dyspnea, blurred vision.</li>
<li>Understand the possibility of drug-induced menstrual irregularities before starting treatment.</li>
<li>Avoid prolonged sun exposure, especially if skin is unprotected. Apply sunscreen lotions (SPF 12 or greater) to all exposed
            skin surfaces.
         </li>
<li>Avoid OTC drugs unless specifically prescribed by the physician; particularly OTC pain medicines.</li>
<li>Report onset of tenderness or redness in an extremity.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>